Actively Recruiting
Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
Led by Northern Jiangsu People's Hospital · Updated on 2026-03-31
20
Participants Needed
1
Research Sites
78 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.
CONDITIONS
Official Title
Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.
- Splenomegaly with secondary hypersplenism.
- No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.
- Underwent laparoscopic splenectomy at our center.
- Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3.
- subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3
- Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3.
- Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12.
- Developed portal vein thrombosis after 12 months post-surgery.
- Provided informed consent to participate in the study.
You will not qualify if you...
- Hepatocellular carcinoma or any other malignancy.
- Hypercoagulable state other than the liver disease related.
- DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.
- Portal hypertension bleeding .
- Child - Pugh C
- Recent peptic ulcer disease
- History of Hemorrhagic stroke
- Pregnancy.
- Uncontrolled Hypertension
- Human immunodeficiency virus (HIV) infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Medical College
Yangzhou, Jiangsu, China, 225001
Actively Recruiting
Research Team
G
Guo-Qing Jiang
CONTACT
D
Dou-Sheng Bai
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here